Fusen Pharmaceutical Company Limited (HKG:1652)
Hong Kong · Delayed Price · Currency is HKD 0.9300
+0.0400 (4.49%)
At close: Feb 13, 2026
HKG:1652 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 240.99 | 326.03 | 565.61 | 491.76 | 385.66 | 486.85 | |
Revenue Growth (YoY) | -43.36% | -42.36% | 15.02% | 27.51% | -20.78% | 19.51% |
Cost of Revenue | 141.24 | 163.39 | 266.1 | 266.74 | 174.53 | 220.79 |
Gross Profit | 99.76 | 162.64 | 299.51 | 225.02 | 211.13 | 266.07 |
Selling, General & Admin | 98.18 | 141.28 | 214.44 | 173.47 | 156.18 | 186.28 |
Research & Development | 64.08 | 106.26 | 65.2 | 15.18 | - | - |
Other Operating Expenses | -11.68 | -17.73 | -1.58 | -9.03 | -10.97 | -1.95 |
Operating Expenses | 150.59 | 229.81 | 278.05 | 179.61 | 145.22 | 184.33 |
Operating Income | -50.83 | -67.18 | 21.45 | 45.41 | 65.92 | 81.74 |
Interest Expense | -19.89 | -20.14 | -12.58 | -12.38 | -8.24 | -9.43 |
Interest & Investment Income | 0.59 | 0.02 | 0.42 | 1.97 | 2.56 | 1.43 |
Earnings From Equity Investments | -97.38 | -104.1 | -40.62 | -21.02 | -1.97 | 24.25 |
Currency Exchange Gain (Loss) | - | 1.28 | 3.32 | -5.32 | -1.41 | 0.28 |
EBT Excluding Unusual Items | -167.51 | -190.11 | -28.01 | 8.67 | 56.85 | 98.26 |
Impairment of Goodwill | - | - | - | - | - | -7.05 |
Gain (Loss) on Sale of Investments | -0.34 | -0.34 | -0.31 | -37.99 | -21.02 | 2.97 |
Gain (Loss) on Sale of Assets | 0 | 0 | -1.12 | -1.67 | -12.04 | -0.18 |
Asset Writedown | - | - | - | - | - | -15.58 |
Pretax Income | -167.85 | -190.45 | -29.45 | -30.99 | 23.79 | 78.41 |
Income Tax Expense | 7.14 | -1.65 | 6.85 | 3.66 | 7.18 | 15.74 |
Earnings From Continuing Operations | -174.99 | -188.8 | -36.3 | -34.65 | 16.61 | 62.67 |
Minority Interest in Earnings | 0.01 | 0.02 | 0.02 | 0.05 | 0.03 | 7.46 |
Net Income | -174.98 | -188.78 | -36.28 | -34.61 | 16.65 | 70.13 |
Net Income to Common | -174.98 | -188.78 | -36.28 | -34.61 | 16.65 | 70.13 |
Net Income Growth | - | - | - | - | -76.27% | 31.25% |
Shares Outstanding (Basic) | 739 | 740 | 752 | 756 | 770 | 786 |
Shares Outstanding (Diluted) | 739 | 740 | 752 | 756 | 770 | 790 |
Shares Change (YoY) | -0.76% | -1.60% | -0.53% | -1.85% | -2.51% | -1.59% |
EPS (Basic) | -0.24 | -0.26 | -0.05 | -0.05 | 0.02 | 0.09 |
EPS (Diluted) | -0.24 | -0.26 | -0.05 | -0.05 | 0.02 | 0.09 |
EPS Growth | - | - | - | - | -77.58% | 33.57% |
Free Cash Flow | 109.58 | 72.77 | -86.42 | 86.63 | -62.37 | 94.56 |
Free Cash Flow Per Share | 0.15 | 0.10 | -0.12 | 0.12 | -0.08 | 0.12 |
Dividend Per Share | - | - | - | - | 0.009 | 0.009 |
Dividend Growth | - | - | - | - | - | 35.82% |
Gross Margin | 41.39% | 49.88% | 52.95% | 45.76% | 54.74% | 54.65% |
Operating Margin | -21.09% | -20.60% | 3.79% | 9.23% | 17.09% | 16.79% |
Profit Margin | -72.61% | -57.90% | -6.41% | -7.04% | 4.32% | 14.41% |
Free Cash Flow Margin | 45.47% | 22.32% | -15.28% | 17.62% | -16.17% | 19.42% |
EBITDA | -12.92 | -32.5 | 49.56 | 72.33 | 83.35 | 98.14 |
EBITDA Margin | -5.36% | -9.97% | 8.76% | 14.71% | 21.61% | 20.16% |
D&A For EBITDA | 37.91 | 34.68 | 28.1 | 26.92 | 17.43 | 16.4 |
EBIT | -50.83 | -67.18 | 21.45 | 45.41 | 65.92 | 81.74 |
EBIT Margin | -21.09% | -20.60% | 3.79% | 9.23% | 17.09% | 16.79% |
Effective Tax Rate | - | - | - | - | 30.17% | 20.07% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.